Literature DB >> 30016002

Pediatric cancer families' participation in whole-genome sequencing research in Denmark: Parent perspectives.

Anna Byrjalsen1,2, Ulrik Stoltze2, Karin Wadt1, Lisa Lyngsie Hjalgrim2, Anne-Marie Gerdes1,3, Kjeld Schmiegelow2,3, Ayo Wahlberg4.   

Abstract

With an impending introduction of genome sequencing into paediatric oncology to facilitate personalised medicine, this study examines parent perspectives on participating in whole genome sequencing (WGS) research in the difficult weeks following diagnosis. As an embedded part of Sequencing Tumor and Germline DNA-Implications and National Guidelines (STAGING), a project aiming to implement WGS of all newly diagnosed paediatric cancer patients in Denmark, a parent perspective study was conducted by a clinical geneticist and anthropologist to document pragmatic, social and ethical dilemmas. Following genetic counselling, systematic debriefings were held and the anthropologist carried out in-depth parent interviews (N = 30 parents to 15 patients). Parents were approached about STAGING 2-28 days after diagnosis. The majority of interviewed parents reported that an early approach had been feasible for them, a few found it too early. Participation was explained in terms of altruism and a desire to learn more about why their child had developed cancer. A number of parents openly disagreed about the amount of information they wanted reported back. Enrolment in WGS research around the time of diagnosis is feasible, however, flexibility from researchers is essential. Notwithstanding high participation rates and a tendency to choose full disclosure, caution as regards the consequences of participating in WGS research is warranted.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  ethics; parent perspectives; pediatric cancer; whole-genome sequencing

Mesh:

Year:  2018        PMID: 30016002     DOI: 10.1111/ecc.12877

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  6 in total

1.  Return of individual research results from genomic research: A systematic review of stakeholder perspectives.

Authors:  Danya F Vears; Joel T Minion; Stephanie J Roberts; James Cummings; Mavis Machirori; Mwenza Blell; Isabelle Budin-Ljøsne; Lorraine Cowley; Stephanie O M Dyke; Clara Gaff; Robert Green; Alison Hall; Amber L Johns; Bartha M Knoppers; Stephanie Mulrine; Christine Patch; Eva Winkler; Madeleine J Murtagh
Journal:  PLoS One       Date:  2021-11-08       Impact factor: 3.240

Review 2.  Views on genomic research result delivery methods and informed consent: a review.

Authors:  Danya F Vears; Joel T Minion; Stephanie J Roberts; James Cummings; Mavis Machirori; Madeleine J Murtagh
Journal:  Per Med       Date:  2021-04-06       Impact factor: 2.512

3.  Impute.me: An Open-Source, Non-profit Tool for Using Data From Direct-to-Consumer Genetic Testing to Calculate and Interpret Polygenic Risk Scores.

Authors:  Lasse Folkersen; Oliver Pain; Andrés Ingason; Thomas Werge; Cathryn M Lewis; Jehannine Austin
Journal:  Front Genet       Date:  2020-06-30       Impact factor: 4.599

4.  Germline whole genome sequencing in pediatric oncology in Denmark-Practitioner perspectives.

Authors:  Anna Byrjalsen; Ulrik K Stoltze; Anders Castor; Ayo Wahlberg
Journal:  Mol Genet Genomic Med       Date:  2020-06-04       Impact factor: 2.183

5.  Medulloblastoma, macrocephaly, and a pathogenic germline PTEN variant: Cause or coincidence?

Authors:  Jussi-Pekka Tolonen; Anne Hekkala; Outi Kuismin; Hannu Tuominen; Maria Suo-Palosaari; Olli Tynninen; Riitta Niinimäki
Journal:  Mol Genet Genomic Med       Date:  2020-05-17       Impact factor: 2.183

6.  Selection criteria for assembling a pediatric cancer predisposition syndrome gene panel.

Authors:  Anna Byrjalsen; Illja J Diets; Jette Bakhuizen; Thomas van Overeem Hansen; Kjeld Schmiegelow; Anne-Marie Gerdes; Ulrik Stoltze; Roland P Kuiper; Johannes H M Merks; Karin Wadt; Marjolijn Jongmans
Journal:  Fam Cancer       Date:  2021-06-01       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.